These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
656 related articles for article (PubMed ID: 3130534)
1. 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist. Yasuda Y; Kikuchi T; Suzuki S; Tsutsui M; Yamada K; Hiyama T Life Sci; 1988; 42(20):1941-54. PubMed ID: 3130534 [TBL] [Abstract][Full Text] [Related]
2. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. Kikuchi T; Tottori K; Uwahodo Y; Hirose T; Miwa T; Oshiro Y; Morita S J Pharmacol Exp Ther; 1995 Jul; 274(1):329-36. PubMed ID: 7616416 [TBL] [Abstract][Full Text] [Related]
3. Effect of 7-(3-[4-(2,3-dimethylphenyl)piperazinyl]propoxy)- 2(1H)-quinolinone (OPC-4392), a newly synthesized agonist for presynaptic dopamine D2 receptor, on tyrosine hydroxylation in rat striatal slices. Kiuchi K; Hirata Y; Minami M; Nagatsu T Life Sci; 1988; 42(3):343-9. PubMed ID: 2892110 [TBL] [Abstract][Full Text] [Related]
4. Interactions of 7-[3-(4-[2,3-dimethylphenyl]piperazinyl)-propoxy]-2(1H)-quinolinone binding in rat striatum: effects of lesions. Zhang X; Nakata Y; Kikuchi T; Segawa T Pharm Res; 1990 Mar; 7(3):280-2. PubMed ID: 1971105 [TBL] [Abstract][Full Text] [Related]
5. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives. Oshiro Y; Sato S; Kurahashi N; Tanaka T; Kikuchi T; Tottori K; Uwahodo Y; Nishi T J Med Chem; 1998 Feb; 41(5):658-67. PubMed ID: 9513593 [TBL] [Abstract][Full Text] [Related]
6. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors. Claustre Y; Fage D; Zivkovic B; Scatton B J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99. Martin GE; Haubrich DR; Williams M Eur J Pharmacol; 1981 Nov; 76(1):15-23. PubMed ID: 7318920 [TBL] [Abstract][Full Text] [Related]
8. Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats. Fujikawa M; Nagashima M; Inoue T; Yamada K; Furukawa T Pharmacol Biochem Behav; 1996 Apr; 53(4):903-9. PubMed ID: 8801596 [TBL] [Abstract][Full Text] [Related]
9. Dopamine D1 receptor behavioral responsitivity following selective lesions of the striatal patch compartment during development. Neal BS; Joyce JN Brain Res Dev Brain Res; 1991 Jun; 60(2):105-13. PubMed ID: 1832593 [TBL] [Abstract][Full Text] [Related]
10. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation. Hu XT; White FJ Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677 [TBL] [Abstract][Full Text] [Related]
12. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems. Wachtel SR; Hu XT; Galloway MP; White FJ Synapse; 1989; 4(4):327-46. PubMed ID: 2532422 [TBL] [Abstract][Full Text] [Related]
13. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats. Arnt J Eur J Pharmacol; 1985 Jul; 113(1):79-88. PubMed ID: 2931283 [TBL] [Abstract][Full Text] [Related]
14. Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Meller E; Bohmaker K; Namba Y; Friedhoff AJ; Goldstein M Mol Pharmacol; 1987 Jun; 31(6):592-8. PubMed ID: 2885734 [TBL] [Abstract][Full Text] [Related]
15. Agonist and antagonist effects of 3-PPP enantiomers on functional dopamine autoreceptors and postsynaptic dopamine receptors in vitro. Mulder AH; Draper R; Sminia P; Schoffelmeer AN; Stoof JC Eur J Pharmacol; 1985 Jan; 107(3):291-7. PubMed ID: 3979429 [TBL] [Abstract][Full Text] [Related]
16. Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats. Arnt J; Hyttel J J Neural Transm; 1984; 60(3-4):205-23. PubMed ID: 6441835 [TBL] [Abstract][Full Text] [Related]
17. Postsynaptic striatal dopamine agonist or antagonist actions of (+) or (-) 3-PPP and modification after receptor deafferentation. Oberlander C; Boissier JR J Pharmacol; 1983; 14(4):401-4. PubMed ID: 6423905 [TBL] [Abstract][Full Text] [Related]
18. Differential agonist profile of the enantiomers of 3-PPP at striatal dopamine autoreceptors: dependence on extracellular dopamine. Clark D; Salah RS; Galloway MP Synapse; 1991 Jul; 8(3):169-76. PubMed ID: 1948667 [TBL] [Abstract][Full Text] [Related]
19. Evidence for multiple dopamine receptors involved in the modulation of acetylcholine release in the striatum. Hársing LG; Vizi ES Pol J Pharmacol Pharm; 1985; 37(3):383-96. PubMed ID: 2866504 [TBL] [Abstract][Full Text] [Related]
20. Caffeine produces contralateral rotation in rats with unilateral dopamine denervation: comparisons with apomorphine-induced responses. Herrera-Marschitz M; Casas M; Ungerstedt U Psychopharmacology (Berl); 1988; 94(1):38-45. PubMed ID: 3126526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]